State of the Art XXVI International Congress of the World Federation of Hemophilia
This special issue of Haemophilia contains reviews and original research reports from selected scientific sessions presented at the XXVI WFH Congress, Bangkok, Thailand, 17-21 October 2004.
Report on the Annual Global Survey 2003
Compiled annually, the Annual Global Survey (AGS) provides demographic and other data on people with hemophilia, von Willebrand disease, other rare factor deficiencies, and inherited platelet disorders throughout the world.
Economic Benefits of Comprehensive Hemophilia Care
Also Available In: Japanese Patients receiving comprehensive hemophilia care have a lower mortality rate and a lower hospitalization rate for bleeding complications than those treated outside a hemophilia treatment centre.
Benefits of Treating Hemophilia with Factor Concentrate
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic impact of this bleeding disorder on the patient as well as the amount of long-term support required from family, community, and government.
Economic Benefits of Basic Hemophilia Treatment & Care
Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia. Adequate care includes access to a hemophilia treatment centre and to treatment products, and education for healthcare providers, patients, and families.
The Safety of Plasma-Derived versus Recombinant Concentrates
In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.
Making Your Case Effectively: A Guide to Government Relations
Hemophilia societies work with governments and health authorities to raise the level of care so that people with hemophilia can live healthy lives. This monograph provides organizations with some practical guidance to improve the effectiveness of government relations.
Transmissible Agents and the Safety of Coagulation Factor Concentrates
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted approach that includes safety measures at every stage of production is needed to minimize the risk of viral transmission by coagulation factor replacement products.
Small Pool Heat-Treated Intermediate Purity Factor VIII Concentrate
Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and who cannot afford high-purity products.
The Preparation of Single Donor Cryoprecipitate
This monograph provides guidelines for the production of single-donor cryoprecipitate.
Chronic Hemophilic Synovitis: The Role of Radiosynovectomy
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Japanese Reviews the pathogenesis of chronic hemophilic synovitis, its clinical characteristics, and therapeutic options, with special emphasis on radiosynovectomy performed with 32P-chromic phosphate.
The Treatment of Hemophilia Bleeding with Limited Resources
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian Treatment for bleeding in hemophilia involves replacement therapy of the missing coagulation factor, but adequate replacement therapy is not always available. This monograph describes conservative measures that decrease or control bleeding and help prevent future damage.